NADAC acquisition cost data for BYSTOLIC 20 MG TABLET. This is a brand-name medication — generic alternatives may be available at lower prices.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 00456142030 | $5.31 | 2022-01-14 | Rx |
| 00456142090 | $5.31 | 2022-01-14 | Rx |
| 00456142030 | $5.31 | 2022-01-14 | Rx |
| 00456142090 | $5.31 | 2022-01-14 | Rx |
| 00456142030 | $5.31 | 2022-01-14 | Rx |
| 00456142090 | $5.31 | 2022-01-14 | Rx |
| 00456142030 | $5.31 | 2022-01-14 | Rx |
| 00456142090 | $5.31 | 2022-01-14 | Rx |
| 00456142030 | $5.31 | 2022-01-14 | Rx |
| 00456142090 | $5.31 | 2022-01-14 | Rx |
Generic: Nebivolol HCl | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $454.4M | 1,696,815 | 331,104 | $4.78 |
| 2020 | $480.4M | 1,624,203 | 315,742 | $5.02 |
| 2021 | $415.4M | 1,282,818 | 295,749 | $5.30 |
| 2022 | $74.4M | 256,991 | 71,008 | $4.51 |
| 2023 | $23.9M | 73,748 | 26,388 | $5.13 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| New York | $4.2M | 13,003 | 3,988 |
| California | $2.8M | 8,676 | 2,790 |
| New Jersey | $1.8M | 5,186 | 1,990 |
| Florida | $1.6M | 4,814 | 1,855 |
| Texas | $1.5M | 4,804 | 1,957 |
| Pennsylvania | $1.0M | 3,329 | 1,151 |
| Connecticut | $846.2K | 2,222 | 742 |
| Illinois | $828.8K | 2,173 | 836 |
| Georgia | $699.2K | 2,192 | 757 |
| Ohio | $645.2K | 2,102 | 781 |
| Virginia | $542.0K | 1,749 | 786 |
| Indiana | $523.4K | 1,548 | 572 |
| Tennessee | $514.1K | 1,590 | 651 |
| North Carolina | $507.9K | 1,739 | 629 |
| Kentucky | $431.7K | 1,463 | 606 |
| Maryland | $412.6K | 1,189 | 493 |
| South Carolina | $404.2K | 1,232 | 515 |
| Missouri | $395.6K | 1,216 | 458 |
| Arizona | $379.7K | 1,034 | 459 |
| Michigan | $353.9K | 986 | 361 |
| Colorado | $297.8K | 817 | 346 |
| Alabama | $287.3K | 858 | 309 |
| Louisiana | $268.2K | 981 | 374 |
| Wisconsin | $263.2K | 754 | 256 |
| Oklahoma | $199.8K | 642 | 255 |
| Massachusetts | $174.4K | 549 | 202 |
| Puerto Rico | $150.3K | 581 | 87 |
| Nebraska | $147.7K | 608 | 214 |
| Mississippi | $141.5K | 548 | 234 |
| Nevada | $141.1K | 400 | 158 |
| Iowa | $138.8K | 547 | 186 |
| Arkansas | $132.5K | 518 | 183 |
| Oregon | $119.4K | 299 | 119 |
| Kansas | $113.8K | 362 | 142 |
| Washington | $104.2K | 333 | 143 |
| Alaska | $96.9K | 253 | 83 |
| Minnesota | $84.3K | 238 | 82 |
| Rhode Island | $80.1K | 255 | 88 |
| West Virginia | $77.8K | 333 | 154 |
| Idaho | $70.9K | 238 | 65 |
| Delaware | $70.7K | 211 | 107 |
| New Hampshire | $66.3K | 191 | 84 |
| Hawaii | $52.8K | 127 | 46 |
| Utah | $40.1K | 143 | 69 |
| Maine | $38.8K | 100 | 36 |
| New Mexico | $36.7K | 124 | 57 |
| South Dakota | $29.3K | 98 | 36 |
| North Dakota | $24.7K | 92 | 31 |
| Wyoming | $23.5K | 77 | 32 |
| Montana | $18.2K | 68 | 29 |
| Vermont | $15.7K | 67 | 19 |
| District of Columbia | $13.4K | 47 | 35 |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.